Sfoglia per AUTORE
GRAU JJ
Collezione AO Cuneo

  

Items : 2

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

2017
AO Cuneo

Ehrnrooth E; Machiels JH; Solca F; Gibson N; Cong XJ; Krämer N; Dupuis N; Merlano MC; Geoffrois L; Guigay J; Tahara M; Vermorken JB; Haddad RI; Mailliez A; Del Campo JM; Grau JJ; Clement PM; Gauler T; Fayette J; Burtness B; Cohen EEW; Licitra LF;

Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1) in Journal of Clinical Oncology

2015
AO Cuneo

Cohen EEW; Licitra LF; Fayette J; Gauler TC; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis NF; Burtness B; Gibson N; Solca F; Ehrnrooth E; Machiels J-PH;